A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 Months

Author(s):

Joanne M. Langley, Terry M. Nolan, Mika Rämet, Peter C. Richmond, Nelson Rosário Filho, Wouter Haazen, Sara P.H. van den Berg, Kristi Williams, Arangassery Rosemary Bastian, Edmund Omoruyi, Joanna Williams Durkin, Nadine Salisch, Gunter Van Geet, Wilbert van Duijnhoven, Esther Heijnen, Benoit Callendret

Details:

Open Forum Infectious Diseases, Volume 11, Issue 9, 2024-09-01, Article number ofae453

Article Link: Click here

Affiliations:

• UWA Medical School
• The Peter Doherty Institute for Infection and Immunity
• Janssen Vaccines & Prevention B.V.
• Janssen Research & Development
• Janssen Pharmaceutica, Headquarters
• Dalhousie University
• Universidade Federal do Parana
• Tampere University
• Murdoch Children's Research Institute
• The Kids Research Institute Australia
• Janssen Biologics Europe